GreenLight Biosciences joined the Unicorn Club on June 16, 2020 after raising a $102 million Series D funding round led by Morningside. Headquartered in Lexington, Massachusetts, United States, GreenLight Biosciences develops RNA-based products for vaccines, antibody therapies, pandemic preparedness, crop protection, and pollinator health.
Keep reading to learn how GreenLight Biosciences became a leader in RNA-based biotechnologies.
What Is GreenLight Biosciences and What Does It Do?
Founded in 2008, GreenLight Biosciences develops RNA-based solutions for the life sciences and agricultural sectors. Its platform supports vaccine development, antibody therapies, pandemic preparedness, crop management, plant protection, and the health of bees and other pollinators. The company leverages RNA technology to create scalable, precise, and versatile solutions for human health, animal health, and agriculture applications.
How Much Funding Has GreenLight Biosciences Raised?
1. Seed Round
- Amount Raised: $15 million
- Date: 2008–2009
- Lead Investors: Cormorant Asset Management
- Purpose: Launch company and develop initial RNA platform
2. Series A Round
- Amount Raised: $30 million
- Date: 2010–2012
- Lead Investors: Tao Capital Partners
- Purpose: Advance RNA platform, expand R&D, and hire key scientists
3. Series B Round
- Amount Raised: $25 million
- Date: 2013–2015
- Lead Investors: Cormorant Asset Management, Tao Capital Partners
- Purpose: Develop RNA applications for human and agricultural health
4. Series C Round
- Amount Raised: $53 million
- Date: 2016–2018
- Lead Investors: Morningside
- Purpose: Scale manufacturing capabilities and expand product development
5. Series D Round
- Amount Raised: $102 million
- Date: June 16, 2020
- Lead Investors: Morningside
- Purpose: Expand RNA-based products for vaccines, therapeutics, and agriculture
6. Post IPO Round
- Amount Raised: $25 million
- Date: April 7, 2025
- Lead Investors: Public Market Investors
- Purpose: Fund commercial expansion and scale RNA platform
Total Funding Raised: $225 million
Latest Funding Date: April 7, 2025
Latest Known Valuation: Unicorn (>$1 billion)
Key Investors
- Morningside
- Details: Global investment firm supporting biotech and life sciences companies
- Focus Areas: Genomics, RNA therapeutics, and agricultural biotech
- Cormorant Asset Management
- Details: Investment firm backing early-stage biotech and technology companies
- Focus Areas: Genomics, therapeutics, and high-growth life sciences startups
- Tao Capital Partners
- Details: Venture capital firm investing in innovative life sciences and technology startups
- Focus Areas: RNA technology, biotechnology, and sustainable solutions
Where Is GreenLight Biosciences’ Headquarters?
GreenLight Biosciences is headquartered in Lexington, Massachusetts, United States, supporting R&D, manufacturing, and operational teams for its RNA-based products.
What’s Next for GreenLight Biosciences?
GreenLight Biosciences plans to expand its RNA-based solutions for vaccines, therapeutics, and crop protection. The company aims to scale manufacturing, advance pandemic preparedness technologies, and enhance agricultural and pollinator health applications globally.
Get Investor and Funding Insights with TexAu
TexAu provides verified investor and funding data for companies like GreenLight Biosciences. Explore insights on RNA therapeutics, genomics, and high-growth biotech startups.
Sign up for Free to access real time investor and funding intelligence.
